These results suggest that selection of device type and flow rate can influence vascular pulsatility and input impedance, which might affect clinical outcomes.
Each recording underwent a second analysis at 2 weeks following the first analysis to evaluate reproducibility. The effect of data sampling (5-min segment/hour), the system sensitivity to detect 5 ms increase in Q-T, and the ability to assess circadian variation were also evaluated. Results: The fully AQA resulted in identical QT for the first and second analyses, but with obvious errors in Q-T measurements. Compared to the complete onscreen MOR, the 24-hour mean Q-T was longer with AQA (416 Ϯ 41 vs 387 Ϯ 30 ms, p < .001, r = .3). The reproducibility of automatic analysis with complete MOR was very good (Q-T: 387 Ϯ 30 vs 387 Ϯ 30 ms), coefficient of variation (CV) = 0.2%, r = .986, p < .001. The 5-minute mean Q-T intervals correlated well with the hourly mean Q-T intervals (r = .994, p < .001, CV = 1 ms) and both showed a similar circadian variation. The system was sensitive to detect a 5 ms change in Q-T intervals (5 Ϯ 2 ms, CV = 0.6%, r = .998, p < .001). Conclusions. The fully automatic Q-T analysis is not an acceptable method, while the automatic analysis with MOR is a highly sensitive and reproducible method. Data sampling by analyzing 5-minute segments per hour is also sensitive and reproducible. The 12-lead digital Holter technique is suitable for Q-T analysis and may have advantage compared to the serial recordings of large number of standard 12-lead ECGs in the evaluation of drug effects on the Q-T interval.
PurposeLeft ventricular assist device (LVAD) therapy has emerged as a viable means for bridging to transplantation in end-stage heart failure patients. There has been conflicting evidence for the effect of this therapy on myocardial interstitial fibrosis, which may play a role in LVAD-induced myocardial recovery. We seek to elucidate the relationship(s) between changes in fibrosis during LVAD support and the following factors: the type of device implanted (continuous vs pulsatile), the duration and mode of support, and the hemodynamic impact of device operation.MethodsLeft ventricular pressure, aortic pressure (AoP), aortic flow, and VAD flow waveforms were recorded intraoperatively at the time of LVAD implant and explant. Myocardial tissue samples were obtained from the left ventricle at time of implant and explant. Collagen-stained tissue samples (1 pre- and 1 post-VAD slide for each of three patients) were analyzed for percent fibrosis. All methods were executed as part of an IRB-approved clinical study, with appropriate informed consent of all involved patients.ResultsAt present, three patients have undergone both LVAD implantation and explantation. Those patients receiving a continuous-flow LVAD (CF-LVAD, n = 2) demonstrated a reduction in percent fibrosis from time of LVAD implant to time of explant, whereas those receiving a pulsatile-flow LVAD (PF-LVAD, n = 1) demonstrated an increase in percent fibrosis. Furthermore, of the two continuous-flow patients, the patient with lower preimplant fibrosis demonstrated a greater reduction in percent fibrosis during the duration of support, evidenced by changes from 4.9 to 2.4% fibrosis and 9.8 to 9.0% fibrosis during LVAD support in these two patients. Hemodynamic recordings indicate a marked reduction in pulsatility of AoP with the CF-LVAD vs the PF-LVAD, which preserves physiological pulsatility. Also, following LVAD support in a CF-LVAD patient, baseline AoP was decreased from pre-VAD status.ConclusionsThe type of device and level of preimplant fibrosis may play a role in determining the direction and magnitude of change in myocardial fibrosis due to LVAD support. Moreover, clear differences in the hemodynamic impact of these two devices might reflect an underlying mechanism for the different changes in fibrosis seen with these two device types. In future work, more complete hemodynamic data will be used to calculate indices of function that will be correlated with histological findings in order to strengthen our understanding of the relationship between structural and functional changes brought about by LVAD support.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.